LBI-1026
THERAPEUTIC AREA
CANNABINOID THERAPIES
Indications
Pain, Nausea & Vomiting, Epilepsy, Neuropathy, Glaucoma
REGULATORY PATHWAY
Improved 505(b)(2) Formulations
TARGET INDICATION
First non-toxic dosage forms of CBD & THC: IV, Inhalation, Oral & Ophthalmic
CURRENT DEVELOPMENT STATUS
Pre-clinical 55 nanometer CBD based formulation complete. New LASSN Cannabis patents filed March 2019. Development is paused until funding is secured. Non-binding Memorandum of understanding has been executed and securities council retained
NEXT DEVELOPMENT PHASE
Formulating and licensing to include THC, bioavailability, safety & efficacy animal models, San Diego development laboratory
TIME TO HUMAN BENEFIT
Recreational products within 1.5 ears and first FDA approved human trials 2 years from funding and staffing
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire